Medtronic plc
Close on Oct 19, 2026
- Market cap
- $119.22B
- P/E (TTM)
- 22.8
- Dividend yield
- 3.06%
Earnings
Next report expected Nov 17, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jul 31, 2026 | Sep 1, 2026 | Before market open | $9.76B | $1.14 | $1.45 |
| Q4 FY2026 Ended Apr 24, 2026 | Jun 3, 2026 | Before market open | $9.81B | $0.96 | $1.55 |
| Q3 FY2026 Ended Jan 23, 2026 | Feb 17, 2026 | Before market open | $9.00B | $0.89 | $1.36 |
| Q2 FY2026 Ended Oct 24, 2025 | Nov 18, 2025 | Before market open | $8.96B | $1.07 | $1.36 |
| Q1 FY2026 Ended Jul 25, 2025 | Aug 19, 2025 | Before market open | $8.58B | $0.81 | $1.26 |
| Q4 FY2025 Ended Apr 25, 2025 | May 21, 2025 | Before market open | $8.90B | $0.82 | $1.62 |
| Q3 FY2025 Ended Jan 24, 2025 | Feb 18, 2025 | Before market open | $8.29B | $1.01 | $1.39 |
| Q2 FY2025 Ended Oct 25, 2024 | Nov 19, 2024 | Before market open | $8.40B | $0.99 | $1.26 |
| Q1 FY2025 Ended Jul 26, 2024 | Aug 20, 2024 | Before market open | $7.92B | $0.80 | $1.23 |
| Q4 FY2024 Ended Apr 26, 2024 | May 23, 2024 | Before market open | $8.59B | $0.49 | $1.46 |
| Q3 FY2024 Ended Jan 26, 2024 | Feb 20, 2024 | Before market open | $8.09B | $0.99 | $1.30 |
Company guidance
Outlook given with results on Sep 1, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| diluted non-GAAP EPSnon-GAAP | FY27 | $5.94 to $6.00 | Raised |
| organic revenue growthnon-GAAP | FY27 | 7.25% to 7.75% growth | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Medtronic filed with the SEC
Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
Results of operations · EX-99.1 to Form 8-K
Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
Results of operations · EX-99.1 to Form 8-K
Medtronic statement on unauthorized system access
Regulation FD disclosure · EX-99.1 to Form 8-K
Medtronic reports strong third quarter
Results of operations · EX-99.1 to Form 8-K
Medtronic reports strong second quarter
Results of operations · EX-99.1 to Form 8-K
11 th quarter in a row of mid-single digit organic revenue growth;
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities
Results of operations · Executive or director change · EX-99.2 to Form 8-K
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results;
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Medtronic announces intent to separate Diabetes business
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation
Results of operations · EX-99.1 to Form 8-K
Delivering on commitments, executing ahead of expectations, and raising guidance
Results of operations · EX-99.1 to Form 8-K
Medtronic announces departure of Karen Parkhill, Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
Medtronic reports full year and fourth quarter
Results of operations · EX-99 to Form 8-K
Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth;
Results of operations · Executive or director change · EX-99 to Form 8-K
Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals
Results of operations · EX-99.1 to Form 8-K
Medtronic reports full year and fourth quarter
Results of operations · EX-99.1 to Form 8-K
Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios
Results of operations · EX-99.1 to Form 8-K
Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes
Results of operations · EX-99.1 to Form 8-K
Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe
Results of operations · EX-99.1 to Form 8-K
Medtronic reports full year and fourth quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Medtronic and DaVita announce new kidney health technology company
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes
Results of operations · EX-99.1 to Form 8-K
Medtronic Diabetes receives FDA warning letter
Regulation FD disclosure · EX-99.1 to Form 8-K
Company continued to launch new products, win share, and deliver strong earnings growth; market procedure volumes impacted by COVID-19 resurgence
Results of operations · EX-99.1 to Form 8-K
MEDTRONIC REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS; ANNOUNCES 9% DIVIDEND INCREASE
Results of operations · EX-99.1 to Form 8-K
SEAN SALMON NAMED EVP & PRESIDENT CARDIOVASCULAR PORTFOLIO;
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL
Results of operations · Other events · EX-99.1 to Form 8-K
Medtronic Announces the Upsizing of its Maximum Tender Offer to up to $4.35 billion for Certain Outstanding Debt Securities Issued by
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medtronic Announces Cash Tender Offers for up to $4.175 billion of Outstanding Debt Securities Issued by Medtronic, Inc., Medtronic Global
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medtronic Announces Closing of Public Offering of Senior Notes; Acceptance of Tendered Notes; and
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc.
Other events · EX-99.1 to Form 8-K
Medtronic Announces the Early Results of its Cash Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and
Other events · EX-99.2 to Form 8-K
Medtronic Announces the Pricing Terms of its Cash Tender Offers for Certain
Other events · EX-99.3 to Form 8-K
MEDTRONIC REPORTS THIRD QUARTER EARNINGS
Regulation FD disclosure · EX-99.1 to Form 8-K